Virbac: Stifel now a buyer

(CercleFinance.com) - On Tuesday Stifel upgraded Virbac shares from "hold" to "buy", while lowering its target price for them from 402 euros to 342 euros (cp: 290 euros, +0.
4%).

In a report on the animal health sector, the analyst believes that the current share price of the French pharmaceutical company does not reflect the turnaround that it has managed to achieve over the past five years.

Analysts do not believe that its stockmarket valuation reflects the improvement in the business linked to the Covid-19 crisis, nor the effect of the sale of the Sentinel brand, which has enabled the company to reduce its debt and invest in its capacities in order to rekindle growth.

With the strategic reorientation of its product portfolio towards blockbusters, the development of its animal feed range and the acceleration of its vaccine activities, Stifel expects Virbac to generate average annual EPS growth of 9% through to 2026.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.